|
private:asceneuron
|
2924417
|
Nov 18th, 2019 12:00AM
|
Asceneuron SA
|
751
|
16.00
|
Open
|
Biotechnology
|
Nov 18th, 2019 03:45PM
|
Nov 18th, 2019 03:45PM
|
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
MISSION
We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.
To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).
HISTORY
Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.
PIPELINE
Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290.
Further information: www.asceneuron.com
|
Open
|
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology
|
Open
|
EPFL Innovation Park, Bâtiment B
|
Lausanne
|
Vaud
|
CH
|
CH-1015
|
|
Asceneuron
|
Health Care
|
Health Care Equipment & Services
|
|
private:asceneuron
|
2924417
|
Nov 16th, 2019 12:00AM
|
Asceneuron SA
|
751
|
16.00
|
Open
|
Biotechnology
|
Nov 16th, 2019 03:56PM
|
Nov 16th, 2019 03:56PM
|
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
MISSION
We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.
To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).
HISTORY
Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.
PIPELINE
Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290.
Further information: www.asceneuron.com
|
Open
|
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology
|
Open
|
EPFL Innovation Park, Bâtiment B
|
Lausanne
|
Vaud
|
CH
|
CH-1015
|
|
Asceneuron
|
Health Care
|
Health Care Equipment & Services
|
|
private:asceneuron
|
2924417
|
Nov 15th, 2019 12:00AM
|
Asceneuron SA
|
750
|
16.00
|
Open
|
Biotechnology
|
Nov 15th, 2019 12:38PM
|
Nov 15th, 2019 12:38PM
|
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
MISSION
We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.
To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).
HISTORY
Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.
PIPELINE
Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290.
Further information: www.asceneuron.com
|
Open
|
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology
|
Open
|
EPFL Innovation Park, Bâtiment B
|
Lausanne
|
Vaud
|
CH
|
CH-1015
|
|
Asceneuron
|
Health Care
|
Health Care Equipment & Services
|
|
private:asceneuron
|
2924417
|
Nov 14th, 2019 12:00AM
|
Asceneuron SA
|
750
|
16.00
|
Open
|
Biotechnology
|
Nov 14th, 2019 05:54PM
|
Nov 14th, 2019 05:54PM
|
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
MISSION
We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.
To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).
HISTORY
Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.
PIPELINE
Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290.
Further information: www.asceneuron.com
|
Open
|
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology
|
Open
|
EPFL Innovation Park, Bâtiment B
|
Lausanne
|
Vaud
|
CH
|
CH-1015
|
|
Asceneuron
|
Health Care
|
Health Care Equipment & Services
|
|
private:asceneuron
|
2924417
|
Nov 13th, 2019 12:00AM
|
Asceneuron SA
|
748
|
16.00
|
Open
|
Biotechnology
|
Nov 13th, 2019 01:06PM
|
Nov 13th, 2019 01:06PM
|
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
MISSION
We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.
To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).
HISTORY
Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.
PIPELINE
Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290.
Further information: www.asceneuron.com
|
Open
|
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology
|
Open
|
EPFL Innovation Park, Bâtiment B
|
Lausanne
|
Vaud
|
CH
|
CH-1015
|
|
Asceneuron
|
Health Care
|
Health Care Equipment & Services
|
|
private:asceneuron
|
2924417
|
Nov 12th, 2019 12:00AM
|
Asceneuron SA
|
748
|
16.00
|
Open
|
Biotechnology
|
Nov 12th, 2019 02:48PM
|
Nov 12th, 2019 02:48PM
|
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
MISSION
We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.
To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).
HISTORY
Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.
PIPELINE
Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290.
Further information: www.asceneuron.com
|
Open
|
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology
|
Open
|
EPFL Innovation Park, Bâtiment B
|
Lausanne
|
Vaud
|
CH
|
CH-1015
|
|
Asceneuron
|
Health Care
|
Health Care Equipment & Services
|
|
private:asceneuron
|
2924417
|
Nov 11th, 2019 12:00AM
|
Asceneuron SA
|
747
|
16.00
|
Open
|
Biotechnology
|
Nov 11th, 2019 02:46PM
|
Nov 11th, 2019 02:46PM
|
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
MISSION
We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.
To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).
HISTORY
Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.
PIPELINE
Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290.
Further information: www.asceneuron.com
|
Open
|
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology
|
Open
|
EPFL Innovation Park, Bâtiment B
|
Lausanne
|
Vaud
|
CH
|
CH-1015
|
|
Asceneuron
|
Health Care
|
Health Care Equipment & Services
|
|
private:asceneuron
|
2924417
|
Nov 10th, 2019 12:00AM
|
Asceneuron SA
|
746
|
16.00
|
Open
|
Biotechnology
|
Nov 10th, 2019 05:52PM
|
Nov 10th, 2019 05:52PM
|
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
MISSION
We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.
To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).
HISTORY
Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.
PIPELINE
Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290.
Further information: www.asceneuron.com
|
Open
|
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology
|
Open
|
EPFL Innovation Park, Bâtiment B
|
Lausanne
|
Vaud
|
CH
|
CH-1015
|
|
Asceneuron
|
Health Care
|
Health Care Equipment & Services
|
|
private:asceneuron
|
2924417
|
Nov 9th, 2019 12:00AM
|
Asceneuron SA
|
746
|
16.00
|
Open
|
Biotechnology
|
Nov 9th, 2019 05:20PM
|
Nov 9th, 2019 05:20PM
|
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
MISSION
We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.
To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).
HISTORY
Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.
PIPELINE
Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290.
Further information: www.asceneuron.com
|
Open
|
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology
|
Open
|
EPFL Innovation Park, Bâtiment B
|
Lausanne
|
Vaud
|
CH
|
CH-1015
|
|
Asceneuron
|
Health Care
|
Health Care Equipment & Services
|
|
private:asceneuron
|
2924417
|
Nov 8th, 2019 12:00AM
|
Asceneuron SA
|
745
|
16.00
|
Open
|
Biotechnology
|
Nov 8th, 2019 02:30PM
|
Nov 8th, 2019 02:30PM
|
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases.
MISSION
We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.
To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).
HISTORY
Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.
PIPELINE
Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290.
Further information: www.asceneuron.com
|
Open
|
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, Biotechnology
|
Open
|
EPFL Innovation Park, Bâtiment B
|
Lausanne
|
Vaud
|
CH
|
CH-1015
|
|
Asceneuron
|
Health Care
|
Health Care Equipment & Services
|